CoChat

CYP21 Genotype, Adult Height, and Pubertal Development in 55 Patients Treated for 21-Hydroxylase Deficiency

The DOI matches its Crossref record; 33 of the 37 references it cites were found in a registry or an index.

Abstract

In a retrospective study we evaluated long-term growth, pubertal developmental patterns to final height (FH), and medication in 55 patients (35 females) affected by 21-hydroxylase deficiency. The patients were classified into 3 groups according to predicted mutation severity: group A (11 women and 9 men), homozygous or compound heterozygous for null or In2 splice mutations [residual enzymatic activity (RA), <1%]; group B (11 women and 4 men), homozygous for I172N or R341P or R426H mutations (RA, approximately 2-3%) or compound heterozygous with any of the group A or B mutations; and group C (13 women and 7 men), homozygous for P30L or V281L or P453S mutations (RA, >30%) or compound heterozygous with any of the group A, B, or C mutations. Three patients showed unclassifiable genotypes. FH was similar in the female groups, whereas male patients in group B were shorter than males in groups A and C. Fifty-five percent of patients in group A, 33% in group B, and 40% in group C reached an FH within 0.5 SD of target height. Four of the 7 patients diagnosed via neonatal screening achieved an FH equal to or above the target height. In the entire group, early diagnosis (<1 yr) improved height outcome. Early diagnosed CAH patients who received lower cortisol equivalent doses during the first year of life reached a better FH. Our results underline the importance of mineralocorticoid therapy, as CAH subjects in groups A and B who did not receive this treatment showed reduced FH. Early diagnosis, the use of more physiological cortisol equivalent dosages during the first year of life, and the extension of mineralocorticoid therapy to all classical patients are shown to improve the auxological outcome. Genotypic analysis helped to interpret the height results of our cases and prospectively may represent a useful tool for improving the therapeutic choice and the height outcome.

Overview

Integrity signals

Registry

Crossref · 10.1210/jc.2003-030123

Cites

33 of 33 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Research works printed but not linked: 4

  1. Aicardi, 1986, Affidabilitá dei più comuni metodi di previsione della statura adulta in un campione di adolescenti italiani., Acta Med Auxol, 18, 55
  2. Ehrlich, 1989, Electrolyte metabolism, 1594
  3. Styne, 1977, Growth patterns in congenital adrenal hyperplasia: correlation of glucocorticoid therapy with stature, In: Lee PA, Plotnick LP, Kowarski AA, Migeon CJ, eds. Congenital adrenal hyperplasia. Baltimore: University Park Press;, 247
  4. New, 1989, Final height in classical and non classical 21-hydroxylase deficiency adrenal hyperplasis, In: Bierich JR, Cacciari E, Raiti S, eds. Growth abnormalities. New York: Raven Press;, 51

Cited by

See all 112

Metadata

Authors
Balsamo, A., Cicognani, A., Baldazzi, L., Barbaro, M., Baronio, F., Gennari, M., Bal, M., Cassio, A., Kontaxaki, K., & Cacciari, E.
Affiliations
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola (IT)
Corresponding author
Cacciari, Emanuele
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2003-12-01
Volume
88
Issue
12
Pages
5680-5688
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W2074732687
Cited by
102
References
37
Citations by year
2026: 2 · 2025: 3 · 2024: 3 · 2023: 4 · 2022: 4 · 2021: 2 · 2020: 6 · 2019: 3 · 2018: 5 · 2017: 2 · 2016: 2 · 2015: 2 · 2014: 3 · 2013: 10 · 2012: 2
FWCI
1.15
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed (publishedVersion)
  • Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
Keywords
21-hydroxylase deficiency, congenital adrenal hyperplasia, adult height, pubertal development, mineralocorticoid therapy, early diagnosis, newborn screening, residual enzyme activity, compound heterozygosity, genotype-phenotype correlation, growth outcomes
MeSH terms
Adrenal Hyperplasia, Congenital, Aging, Body Height, Child, Child, Preschool, Female, Fertility, Genotype, Humans, Infant, Infant, Newborn, Male, Mineralocorticoids, Prognosis, Puberty, Retrospective Studies, Steroid 21-Hydroxylase

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.